Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities

Introduction

The report analyzes current and potential world molecular diagnostics markets and advances in the field. The report forecasts future growth to 2015, and segments the market by test and geography. Also included are profiles of companies marketing key products, and analyses of key drivers.

Scope

- Explains how molecular diagnostics represents a business opportunity for the IVD industry.
- Evaluates drivers and trends behind the growth of molecular diagnostics.
- Reviews key challenges facing molecular diagnostic manufacturers and companies seeking to enter the market.
- Analyzes markets by key types of testing, product, and country, and reviews top products and opportunities.
- Profiles key players, including established companies and growing firms with innovative technologies.

Research and Analysis Highlights

Two important growth drivers in the clinical setting for molecular diagnostics include the need for new biomarker assays as well as for techniques that lower the cost per test, and which improve ease of use, data quality and turnaround time.

By far, most of the established market for molecular diagnostics lies in the North American region. The market is building in Europe, but is still at relatively an early stage in the rest of the world. Geographically, the US and European markets are the most advanced in terms of adoption of molecular testing and make up the majority of the market.

In the current market for HPV, only about 20% of women over the age of 30 are screened for HPV using DNA-based tests in conjunction with a standard Pap smear, which leaves a lot of room for market growth.

Key Reasons to Purchase this Research

- Understand each market in terms of size as well as its future potential.
- Understand which key products are already in the market place for each market segment analyzed.
- Evaluates which segment future opportunities may lie for companies.
- Understand key issues & challenges facing molecular diagnostics makers & their component suppliers thus helping potential entrants review the issues
- Learn about possible products from recent market developments mentioned in the report.
Table of Contents

Advances in molecular diagnostics

Executive summary 12

Introduction 12
Trends and drivers 13
Market developments 14
Markets 15

Chapter 1 Introduction 18

Summary 18
Perspective 19

Perspective 19
An emerging science 19
Understanding the human genome 21
Molecular level analysis 22
Personalized care 22
Individualized response 23

Early-stage diagnosis 25
Infectious disease 26
Viruses 27
Oncology 28

Diagnostics business opportunity 30
A growing role in diagnostics 30
Companion diagnostics and therapies 31
Diagnostics allowing early detection and treatment 32
Increased efficiency 33
Optimizing drug therapy 33
Significant regulatory concerns 34
Strengthening oversight 34
Improving patient outcomes 36
Optimizing instrumentation and chemistries 38
Advances in sample preparation needed 39
Automation 41
Chapter 2 Trends and drivers 48

Summary 48
Integral to traditional labs 49
Improved assay/test efficiencies 50
Targeting antibiotic resistance 52
Next generation ultrasensitive molecular diagnostics 54
Platform variety 55
PCR 56
Microfluidics 58
Biochips/microarrays 59
Others 60
Challenges and issues 62
Re-emergence of infectious diseases and other threats 64
Establishing accepted regulatory processes 66
Reimbursement 68
Medicare coverage 69

Chapter 3 Market developments 7

Summary 72
Extracting microRNAs from tissue 73
Cystic fibrosis genetic screening 74
PET scanning 75
Expanded medicare coverage 76
Ionian Technologies-Roche collaboration 77
Leukemia diagnostic kit cleared 77
New lung cancer test 78
AMD diagnostic 79
Key biomarker gene 80
Point of care instrumentation 81
Genotyping test launch 82
Innovative colon cancer diagnostic 83
Innovative pancreatic cancer diagnostic 84
Brain cancer companion diagnostic 85
Rapid thermocycling 86
Acquisition of AcroMetrix 87
Real-time PCR 87
APiX detection kit 88
Chapter 4 Markets 92

Summary 92
Overview 93
Growth drivers 94
Future opportunities 95

World market forecasts 99
Geographical segmentation 101
Type of testing 103
Blood screening 103
HPV testing 105
Hospital acquired infections 108
HIV/HCV testing 110
Genetic testing 113
Oncology 116
STD testing 118

Chapter 5 Corporate profiles 124

Abbott Molecular 124
Company description 124

AcroMetrix 125
Company description 125

Adnavance Technologies Inc. 126
Company description 126

Affymetrix 127
Company description 127

Asuragen Inc. 128
Company description 128

AutoGenomics Inc. 129
Company description 129

Beckman Coulter Inc. 130
Company description 130

Becton Dickinson 131
Company description 131
Biocartis SA 132
Company description 132
BioHelix 133
Company description 133
bioMérieux SA 134
Company description 134
Bio-Rad Laboratories Inc. 135
Company description 135
Celera 136
Company description 136
Cepheid 137
Company description 137
CombiMatrix Corp. 138
Company description 138
CytoCell Ltd. 139
Company description 139
DiagnoCure Inc. 140
Company description 140
Diasorin SpA 141
Company description 141
Dx Assays 142
Company description 142
EliTech Group 143
Company description 143
Enzo Biochem 144
Company description 144
EraGen Biosciences 145
Company description 145
Fujirebio Diagnostics Inc. 146
Company description 146
Gen-Probe Inc. 147
Company description 147
Gene Express Inc. 148
Company description 148
GE Healthcare 149
Company description 149
Genomic Health Inc. 150
Chapter 6 Appendix 180

List of Figures

Figure 1.1: Molecular diagnostics: predicting response, early treatment of disease 25
Figure 2.2: Molecular Diagnostics 29
Figure 2.3: Integrating molecular diagnostics with therapeutics 32
Figure 2.4: Changing treatment protocols in clinical practice 42
Figure 3.5: Clinical potential of molecular diagnostics 49
Figure 3.6: Molecular diagnostics: challenges for developers 64
Figure 5.7: World Market for molecular diagnostics by geography, 2010 103
Figure 5.8: World Market for molecular diagnostics by application, 2010 103
List of Tables

Table 5.1: Key players in molecular diagnostics 100
Table 5.2: World market for molecular diagnostics, 2009-2015, ($m) 101
Table 5.3: World Market for molecular diagnostics by geography, 2010, ($m) 102
Table 5.4: World Market for molecular diagnostics by application, 2010, ($m) 102
Table 5.5: Molecular diagnostics blood screening market, breakup by competition, ($m) 105
Table 5.6: Molecular diagnostics HPV testing market, breakup by competition, ($m) 108
Table 5.7: Molecular diagnostics hospital acquired infections testing market, breakup by competition, ($m) 109
Table 5.8: Molecular diagnostics HIV/HCV testing market, breakup by competition, ($m) 112
Table 5.9: Molecular diagnostics genetic testing market, breakup by competition, ($m) 116
Table 5.10: Molecular diagnostics oncology testing market, breakup by competition, ($m) 118
Table 5.11: Molecular diagnostics STD testing market, breakup by company, ($m) 122